This inventor holds 1 USPTO granted patent. Top assignees: Edisbiotech Co., Ltd., The Asan Foundation, University of Ulsan Foundation for Industry Cooperation. Active years: 2025.
Company Filing History:
1 out of 1 
1 out of 84 
1 out of 94 
Years Active: 2025
Title: Yeong Hui Cho: Innovator in Monoclonal Antibody Development
Introduction
Yeong Hui Cho is a notable inventor based in Hanam, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on enhancing the specificity and affinity of antibodies for better diagnostic applications.
Latest Patents
Yeong Hui Cho holds a patent for a monoclonal antibody specifically binding to CCSP-2. The patent describes a monoclonal antibody that targets the EGF2 domain of colon cancer secreted protein-2 (CCSP-2). This invention demonstrates significantly increased affinity compared to existing peptides and improved specificity over current antibodies targeting CCSP-2. The potential applications of this invention include accurate diagnosis through specific detection of CCSP-2 at the protein level.
Career Highlights
Throughout his career, Yeong Hui Cho has worked with prominent organizations, including the Asan Foundation and Edisbiotech Co., Ltd. His experience in these institutions has allowed him to advance his research and contribute to the field of cancer diagnostics.
Collaborations
Yeong Hui Cho has collaborated with several professionals in his field, including Hye-Nam Son and Eun-Ju Do. These collaborations have enriched his research and fostered innovation in monoclonal antibody development.
Conclusion
Yeong Hui Cho's work in monoclonal antibody research exemplifies the importance of innovation in biotechnology. His contributions have the potential to significantly impact cancer diagnostics and improve patient outcomes.